恶性肿瘤患者在接受化疗、放疗、靶向治疗及免疫治疗等抗肿瘤治疗时都可能引发恶心呕吐。化疗所致恶心呕吐(chemotherapy-induced nausea and vomiting,CINV)是最为常见也是目前研究最为深入的不良反应;放疗所致恶心呕吐(radiation-indu...恶性肿瘤患者在接受化疗、放疗、靶向治疗及免疫治疗等抗肿瘤治疗时都可能引发恶心呕吐。化疗所致恶心呕吐(chemotherapy-induced nausea and vomiting,CINV)是最为常见也是目前研究最为深入的不良反应;放疗所致恶心呕吐(radiation-induced nausea and vomiting,RINV)、靶向治疗及免疫治疗所致恶心呕吐(targeted therapy and immunotherapyinduced nausea and vomiting,TIINV)也越来越受到关注。本专家组在《化疗所致恶心呕吐全程管理上海专家共识(2018年版)》的基础上,根据近年来抗肿瘤治疗所致恶心呕吐(antineoplastic-induced nausea and vomiting,AINV)领域的循证医学新证据,结合上海一线肿瘤治疗专家的实际临床经验,最终形成《抗肿瘤治疗所致恶心呕吐全程管理上海专家共识(2024年版)》,以便进一步在上海地区积极、合理、规范、全程地预防和处理AINV,保障患者的治疗强度和医疗安全。展开更多
1文献来源
Kummel S, Krocker J, Kohls A, et al. Randomized trial: Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer [J]. Sr J Cancer, 2006,94(9) : 1237-1244.
1文献来源
Mamounas EP,Tang G,Fisher B,et al.Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,estrogen receptor-positive breast cancer:Results from NSABP B-1...1文献来源
Mamounas EP,Tang G,Fisher B,et al.Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,estrogen receptor-positive breast cancer:Results from NSABP B-14 and NSABP B-20[J].J Clin Oncol,2010,28(10):1677-1683.展开更多
文摘恶性肿瘤患者在接受化疗、放疗、靶向治疗及免疫治疗等抗肿瘤治疗时都可能引发恶心呕吐。化疗所致恶心呕吐(chemotherapy-induced nausea and vomiting,CINV)是最为常见也是目前研究最为深入的不良反应;放疗所致恶心呕吐(radiation-induced nausea and vomiting,RINV)、靶向治疗及免疫治疗所致恶心呕吐(targeted therapy and immunotherapyinduced nausea and vomiting,TIINV)也越来越受到关注。本专家组在《化疗所致恶心呕吐全程管理上海专家共识(2018年版)》的基础上,根据近年来抗肿瘤治疗所致恶心呕吐(antineoplastic-induced nausea and vomiting,AINV)领域的循证医学新证据,结合上海一线肿瘤治疗专家的实际临床经验,最终形成《抗肿瘤治疗所致恶心呕吐全程管理上海专家共识(2024年版)》,以便进一步在上海地区积极、合理、规范、全程地预防和处理AINV,保障患者的治疗强度和医疗安全。
文摘1文献来源
Kummel S, Krocker J, Kohls A, et al. Randomized trial: Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer [J]. Sr J Cancer, 2006,94(9) : 1237-1244.
文摘1文献来源
Mamounas EP,Tang G,Fisher B,et al.Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,estrogen receptor-positive breast cancer:Results from NSABP B-14 and NSABP B-20[J].J Clin Oncol,2010,28(10):1677-1683.